Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn's DiseaseGlobeNewsWire • 11/11/20
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewsWire • 11/02/20
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)GlobeNewsWire • 10/27/20
Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money ReportGlobeNewsWire • 09/25/20
Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in BrazilGlobeNewsWire • 09/17/20
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem SciencesGlobeNewsWire • 09/16/20
Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in SpecieGlobeNewsWire • 09/16/20
Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration StatementGlobeNewsWire • 08/28/20
Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive InterviewGlobeNewsWire • 08/27/20
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseasesGlobeNewsWire • 08/24/20
Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other CancersGlobeNewsWire • 08/21/20
Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year TermGlobeNewsWire • 08/20/20
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s DiseaseGlobeNewsWire • 08/18/20
Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 PatientsGlobeNewsWire • 08/04/20
Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 millionGlobeNewsWire • 08/03/20
Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 PatientsGlobeNewsWire • 07/31/20
Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIMGlobeNewsWire • 07/30/20
Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020GlobeNewsWire • 07/30/20